30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

Charles Berkman

Track

Insider profile

Currently holds a position at Ligand Pharmaceuticals Inc

Performance

Overall performance
4.2
Performance over holding periods
4.2
30 days 90 days 120 days
Average return 16% 8.2% 15.1%
Success rate 98% 68% 82%
Transactions
12 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Senior Vice President, General Counsel, Secretary Ligand Pharmaceuticals Inc Jan. 1, 2018 -
Vice President, General Counsel, Secretary Ligand Pharmaceuticals Inc April 1, 2007 - Jan. 1, 2018
Charles Berkman's trades of OmniAb Inc's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-07 2026-04-07
US OmniAb Inc (OABI)
S Sale
61,678 -42.4%
478.56
US$178,899 		61,678 -42.4% 478.56 US$178,899
2026-04-07 2026-04-07
US OmniAb Inc (OABI)
PrS Proposed sale
14,789
251.16
US$1,948,938 		14,789 251.16 US$1,948,938
2026-02-18 2026-02-18
US OmniAb Inc (OABI)
S Sale
7,122 -36.2%
226.87
US$297,998 		7,122 -36.2% 226.87 US$297,998
2026-02-17 2026-02-18
US OmniAb Inc (OABI)
PrS Proposed sale
9,541
1.70
US$16,220 		9,541 1.70 US$16,220
2026-02-17 2026-02-17
US OmniAb Inc (OABI)
S Sale
6,990 -1.8%
1.70
US$11,883 		6,990 -1.8% 1.70 US$11,883
2026-02-17 2026-02-17
US OmniAb Inc (OABI)
PrS Proposed sale
6,891
1.70
US$11,715 		6,891 1.70 US$11,715
2025-12-09 2025-12-08
US OmniAb Inc (OABI)
S Sale
8,044 -2.1%
1.96
US$15,766 		8,044 -2.1% 1.96 US$15,766
2025-12-08 2025-12-08
US OmniAb Inc (OABI)
PrS Proposed sale
8,044
1.96
US$15,774 		8,044 1.96 US$15,774
2025-04-07 2025-04-07
US OmniAb Inc (OABI)
PrS Proposed sale
7,206
2.00
US$14,396 		7,206 2.00 US$14,396
2025-04-07 2025-04-07
US OmniAb Inc (OABI)
S Sale
7,206 -1.9%
2.00
US$14,412 		7,206 -1.9% 2.00 US$14,412
2025-02-19 2025-02-19
US OmniAb Inc (OABI)
S Sale
7,255 -2.0%
3.67
US$26,626 		7,255 -2.0% 3.67 US$26,626
2025-02-18 2025-02-19
US OmniAb Inc (OABI)
PrS Proposed sale
7,119
3.68
US$26,199 		7,119 3.68 US$26,199
2025-02-19 2025-02-18
US OmniAb Inc (OABI)
S Sale
8,215 -2.2%
3.68
US$30,231 		8,215 -2.2% 3.68 US$30,231
2025-02-18 2025-02-18
US OmniAb Inc (OABI)
PrS Proposed sale
8,215
3.68
US$30,232 		8,215 3.68 US$30,232
2025-01-22 2025-01-21
US OmniAb Inc (OABI)
S Sale
25,489 -6.9%
3.24
US$82,584 		25,489 -6.9% 3.24 US$82,584
2025-01-21 2025-01-21
US OmniAb Inc (OABI)
PrS Proposed sale
25,489
3.24
US$82,529 		25,489 3.24 US$82,529
2024-12-10 2024-12-09
US OmniAb Inc (OABI)
S Sale
8,022 -2.4%
4.13
US$33,131 		8,022 -2.4% 4.13 US$33,131
2024-12-09 2024-12-09
US OmniAb Inc (OABI)
PrS Proposed sale
8,022
4.13
US$33,094 		8,022 4.13 US$33,094
2024-04-09 2024-04-08
US OmniAb Inc (OABI)
S Sale
6,954 -2.3%
5.27
US$36,648 		6,954 -2.3% 5.27 US$36,648
2024-04-08 2024-04-08
US OmniAb Inc (OABI)
PrS Proposed sale
6,954
5.27
US$36,675 		6,954 5.27 US$36,675
2021-02-05 2021-02-04
S Sale
18,097 -38.5%
178.50
US$3,230,376 		18,097 -38.5% 178.50 US$3,230,376
2020-06-05 2020-06-04
S Sale
11,146 -21.4%
118.59
US$1,321,775 		11,146 -21.4% 118.59 US$1,321,775